20 results about "B Antibody" patented technology

The invention provides a freeze-dried universal platelet rich plasma (PRP) preparation and a preparation process thereof, aiming at solving the problems that the existing PRP is limited in blood type matching, difficult in biological activity preservation, short in validity period and the like. According to the preparation, 18-19% of the type A, 7-8% of the type B and 73-74% of the type AB are mixed with PRP of different blood types and freeze-dried. Tests show that agglutination does not exist in cross blood matching, the titers of the anti-A antibody and the anti-B antibody are both lower than 1: 2, and blood group reaction is effectively avoided. Freeze-drying causes little damage to growth factors, still has biological activity within 24 months, and has a good cell proliferation test effect. Animal experiments show that wound healing can be remarkably promoted. In addition, the culture medium is good in stability in the environment of 4 DEG C, and the moisture, growth factors and the sterile state all meet the requirements. The preparation disclosed by the invention has the advantages of obvious universal advantages, good biological activity preservation and strong stability, and provides a better choice for clinical treatment.

The present invention provides a specific antibody against FGFR2IIIb. Specifically, the invention provides an anti-FGFR2IIIb antibody or an antigen binding fragment thereof, and the anti-FGFR2IIIb antibody or the antigen binding fragment thereof can effectively bind human, mouse and monkey FGFR2IIIb. The invention also provides an antibody drug conjugate and the like of the antibody or the antigen binding fragment, can be applied to preparation of drugs for treating tumors expressing or overexpressing FGFR2IIIb, and has a good application prospect.

1. The material of the article to which this design relates is synthetic resin. 2. The article to which this design relates is a set of teaching tools that can be used to learn about ABO blood types and RhD blood types. 3. Teaching tool A represents red blood cells, teaching tool B represents type A antigens, teaching tool C represents type B antigens, teaching tool D represents RhD antigens, teaching tool E represents anti-type A antibodies, teaching tool F represents anti-type B antibodies, and teaching tool G represents anti-RhD antibodies. 4. The article to which this design relates is designed to easily explain the phenomenon of red blood cells and the antigens present on their surfaces reacting with antibodies in serum. 5. Reference Figures 1 to 3 show the product in use. Reference Figure 1 shows that when type B red blood cells are reacted with a type A person, the anti-B antibodies in the type A serum and the type B red blood cells agglutinate. Reference Figure 2 shows that when type A red blood cells are reacted with a type B person, the anti-A antibodies in the type B serum and the type A red blood cells agglutinate. Reference Figure 3 shows the RhD phenomenon, where red blood cells with RhD antigens on their surface agglutinate with anti-RhD antibodies.

The invention relates to the technical field of tumor diagnosis, in particular to a detection reagent, a kit and application of the detection reagent to detection of tumor markers. The sMIC quantitative detection kit mainly comprises a magnetic separation reagent, an enzyme reactant, a substrate solution, a calibration product and a quality control product, and further comprises a diluent, a buffer solution and a cleaning solution. The magnetic separation reagent is a streptavidin magnetic microsphere coupled biotinylated anti-MICA antibody, the enzyme reactant is an acridinium ester labeled anti-MICA / B antibody, the substrate solution is an enzymatic chemiluminescence substrate solution, and the calibration product and the quality control product are solutions containing recombinant MICA / B protein. According to the reagent and the kit provided by the invention, by optimizing a coupling process and reaction system design of the magnetic beads and the antibodies, the coupling efficiency of the magnetic beads and the antibodies is improved, and the detection sensitivity and the anti-interference capability are remarkably improved.

Provided herein are anti-CD3 × anti-MICA / B antibodies and methods of using such antibodies for the treatment of cancers.

The invention relates to an anti-MICA / B antibody and application thereof, and belongs to the field of biological medicine. Specifically, the invention discloses a specific binding MICA / B antibody or an antigen binding fragment thereof, a nucleic acid molecule, an expression vector, a method for preparing the antibody or the antigen binding fragment thereof, a recombinant cell, a composition, and especially application in preparation of drugs for treating and / or preventing tumors. Meanwhile, the provided antibody has strong specificity, high affinity, an inhibition effect of preventing MICA / B from falling off, and an effect of mediating cell endocytosis.

The invention discloses an affinity chromatography medium for removing an anti-A / anti-B antibody and a preparation method and application of the affinity chromatography medium, the general formula of the chromatography medium is shown in the formula I. M is a matrix, A comprises 2-15 carbon atoms and further comprises one or more hydroxyl groups and / or-NH-,-O-or-S-, S is a straight-chain or branched-chain alkyl group with 1-17 carbon atoms, and the formula I is shown in the description. D is a straight chain or branched chain alkyl group with 1-17 carbon atoms, n is 1 or 2, and T is a blood type saccharide ligand. The chromatography medium obtained in the invention has good stability and binding capacity.

The invention relates to a high-risk HPV (human papillomavirus)-related fusion protein. The high-risk HPV-related fusion protein has an amino acid sequence as shown in SEQ ID NO. 1 or SEQ ID NO. 3. According to the fusion protein disclosed by the invention, by virtue of an antigen epitope chimeric technology, specific immunogenic regions of various subtypes of 15 high-risk HPV are reserved, and interference among sequences is eliminated, so that a recombinant fusion protein is obtained, and high-risk, low-risk and uninfected samples are distinguished by a single protein, so that the clinical diagnosis efficiency is improved, and the clinical application prospect is wide. Multiple operations of traditional typing detection are replaced by single detection, the cost is reduced, and the detection time is shortened. Fusion protein is used as an immunogen immune animal, a single B antibody preparation technology is adopted to screen antibodies with high and medium titers, a rapid test strip is prepared, and high-risk and low-risk identification is conveniently and rapidly carried out on suspected HPV patients; when the detection result is negative, the patient is not infected or is only infected with low-risk HPV, and the patient is not infected with high-risk HPV, so that medical personnel can conveniently take further typing detection, treatment and other measures in time.

The present application relates to an anti-MICA / B antibody and application thereof, and belongs to the field of biological medicine. Specifically, specific binding MICA / B antibody or antigen binding fragment thereof, nucleic acid molecule, expression vector, method for preparing the antibody or antigen binding fragment thereof, recombinant cell, composition, and particularly use in preparing a medicament for treating and / or preventing tumors are disclosed. Meanwhile, the provided antibody is specific, has high affinity, inhibits the shedding of MICA / B, and mediates intracellular endocytosis.

This invention relates to the fields of biomedicine and immunology, and particularly to the preparation and application of an anti-Staphylococcal enterotoxin B antibody. The antibody provided by this invention has a SEB-A8 heavy chain variable region containing CDR sequences as shown in SEQ ID NO:1-3, and a light chain variable region containing CDR sequences as shown in SEQ ID NO:9-11. It has significant application value in the treatment, prevention, and diagnosis of Staphylococcus aureus infections. Experimental data show that this antibody can effectively neutralize the superantigen activity of SEB, significantly improve the survival rate of MRSA-infected mice, and exhibit a dose-dependent protective effect. It can be used as a "non-antibiotic" treatment strategy for the treatment of methicillin-resistant Staphylococcus aureus infections, which is of great significance in controlling the development of bacterial resistance and provides a new research direction for clinical anti-infective therapy.

Provided herein are antibodies that specifically bind to MICA / B having heavy chain, light chain, variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) disclosed herein, as well as methods and uses thereof.

The invention relates to an anti-MICA / B antibody and application thereof, and belongs to the field of biological medicine. Specifically, the invention discloses a specific binding MICA / B antibody or an antigen binding fragment thereof, a nucleic acid molecule, an expression vector, a method for preparing the antibody or the antigen binding fragment thereof, a recombinant cell, a composition, and especially application in preparation of drugs for treating and / or preventing tumors. Meanwhile, the provided antibody has strong specificity, high affinity, an inhibition effect of preventing MICA / B from falling off, and an effect of mediating cell endocytosis.

Provided herein are methods of treating cancer with an antibody that specifically binds to MICA / B, or an antigen-binding fragment thereof, having a heavy chain, a light chain, a variable heavy chain domain (VH), a variable light chain domain (VL), and a complementarity determining region (CDR) disclosed herein.

This invention discloses a composite material based on hollow mesoporous carbon spheres loaded with ABO blood group monoclonal antibodies, comprising hollow mesoporous carbon spheres and ABO blood group monoclonal antibodies loaded on the hollow mesoporous carbon spheres, wherein the ABO blood group monoclonal antibodies are selected from at least one of type A antibodies and type B antibodies. This invention also discloses a method for preparing the composite material, comprising: modifying the surface of the hollow mesoporous carbon spheres with amino groups; dispersing the spheres in an ABO blood group monoclonal antibody solution; and stirring the reaction. This invention immobilizes ABO blood group monoclonal antibodies on the surface of hollow mesoporous carbon spheres, improving the stability, specificity, and sensitivity of the antibodies, and achieving rapid and accurate ABO blood group identification. This invention also discloses a kit comprising the above-mentioned composite material, and the application of this composite material in ABO blood group detection.

Provided herein are antibodies or antigen-binding fragments thereof that specifically bind to MICA / B having heavy chain, light chain, variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) disclosed herein, as well as methods and uses thereof. In certain aspects, the antibodies or an antigen-binding fragment thereof comprise one or more amino acid modifications to enhance effector function compared to the unmodified monoclonal antibody or antigen-binding fragment thereof; and / or lacks fucosylation or comprises reduced fucosylation.

The present application relates to an anti-MICA / B antibody and application thereof, and belongs to the field of biological medicine. Specifically, specific binding MICA / B antibody or antigen binding fragment thereof, nucleic acid molecule, expression vector, method for preparing the antibody or antigen binding fragment thereof, recombinant cell, composition, and particularly use in preparing a medicament for treating and / or preventing tumors are disclosed. Meanwhile, the provided antibody is specific, has high affinity, inhibits the shedding of MICA / B, and mediates intracellular endocytosis.

This specification provides a method for treating cancer using an antibody or antigen-binding fragment thereof that specifically binds to MICA / B, having a heavy chain, a light chain, a heavy chain variable domain (VH), a light chain variable domain (VL), and a complementarity-determining region (CDR) as disclosed herein. In a second aspect, this disclosure provides a method for treating parotid gland cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that binds to MICA / B (an anti-MICA / B antibody).

This disclosure relates to anti-MICA (major histocompatibility complex class I chain related A) and / or anti-MICB (major histocompatibility complex class I chain related B) antibodies, antigen-binding fragments, and the uses thereof.